The COVID-19 pandemic is affecting all of us around the world. Abbott is putting its resources towards helping you navigate this crisis. As a leader in diagnostic testing, we have a unique responsibility to contribute our expertise to help fight the COVID-19 pandemic.
To help provide the critical diagnostic information needed, Abbott is currently providing, and continuing to develop, tests across its diagnostic platforms.
We thank you for your patience and understanding as we do our part to manufacture products that help keep communities safe.
The first-of-its-kind NAVICA™ app helps people navigate daily life in a new normal. NAVICA displays results from the 15-minute BinaxNOW™ COVID-19 Ag Card, a rapid antigen test, to help individuals make informed decisions.
The ID NOW™ COVID-19 assay is now available for use on the ID NOW platform under U.S. Food and Drug Administration Emergency Use Authorization (EUA). The ID NOW™ COVID-19 rapid test delivers high-quality molecular positive results in as little as 5 minutes, targeting the coronavirus (COVID-19) RdRp Gene.
Please sign up by clicking on the yellow button below to be notified when testing becomes available in your area.
This form is intended for professionals or administrators. If you would like additional information about product availability and product news, please complete the form below.
Based on your current location, the content on this page may not be relevant for your country.
